Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Tobacco use cessation | D020340 | — | — | — | 1 | — | 1 | 11 | 13 |
Cigarette smoking | D000073865 | — | — | — | — | — | 2 | 4 | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Tobacco use disorder | D014029 | — | F17 | 4 | 9 | 2 | — | 7 | 19 |
Tobacco use | D064424 | — | — | — | 3 | 2 | — | 12 | 16 |
Addictive behavior | D016739 | EFO_0004347 | — | — | — | 1 | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Smoking | D012907 | EFO_0004318 | — | 3 | 2 | — | — | 5 | 10 |
Smoking cessation | D016540 | EFO_0004319 | — | 4 | 1 | — | — | 3 | 7 |
Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 1 | 1 | — | — | 1 | 2 |
Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 1 | 1 | — | — | 1 | 2 |
Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Harm reduction | D040261 | — | — | 3 | — | — | — | — | 3 |
Marijuana abuse | D002189 | EFO_0007191 | F12 | 1 | — | — | — | — | 1 |
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Tobacco smoking | D000073869 | — | — | — | — | — | — | 3 | 3 |
Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | — | 2 | 2 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 2 | 2 |
Essential hypertension | D000075222 | — | I10 | — | — | — | — | 1 | 1 |
Cerebral infarction | D002544 | — | I63 | — | — | — | — | 1 | 1 |
Infarction | D007238 | EFO_0009463 | — | — | — | — | — | 1 | 1 |
Nicotiana | D014026 | NCBITaxon_4097 | — | — | — | — | — | 1 | 1 |
Compliance | D003187 | — | — | — | — | — | — | 1 | 1 |
Stereotyped behavior | D013239 | HP_0000733 | — | — | — | — | — | 1 | 1 |
Blood pressure | D001794 | EFO_0004325 | — | — | — | — | — | 1 | 1 |
Drug common name | Lobeline |
INN | lobeline |
Description | (-)-lobeline is an optically active piperidine alkaloid having a 2-oxo-2-phenylethyl substituent at the 2-position and a 2-hydroxy-2-phenylethyl group at the 6-position. It has a role as a nicotinic acetylcholine receptor agonist. It is a piperidine alkaloid, a tertiary amine and an aromatic ketone. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1 |
PDB | — |
CAS-ID | 90-69-7 |
RxCUI | — |
ChEMBL ID | CHEMBL122270 |
ChEBI ID | 48723 |
PubChem CID | 101616 |
DrugBank | — |
UNII ID | D0P25S3P81 (ChemIDplus, GSRS) |